X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1074) 1074
Book Review (211) 211
Publication (45) 45
Conference Proceeding (4) 4
Dissertation (3) 3
Book Chapter (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (892) 892
humans (854) 854
oncology (699) 699
zd1839 iressa (552) 552
tyrosine kinase inhibitor (494) 494
zd1839 (462) 462
gefitinib (449) 449
female (375) 375
receptor, epidermal growth factor - antagonists & inhibitors (362) 362
growth-factor receptor (282) 282
antineoplastic agents - therapeutic use (279) 279
male (279) 279
quinazolines - pharmacology (274) 274
quinazolines - therapeutic use (254) 254
egfr (245) 245
cell line, tumor (237) 237
antineoplastic agents - pharmacology (235) 235
cell lung-cancer (230) 230
lung neoplasms - drug therapy (230) 230
middle aged (223) 223
animals (218) 218
receptor, epidermal growth factor - metabolism (214) 214
aged (206) 206
therapy (196) 196
cancer (194) 194
expression (194) 194
iressa (190) 190
carcinoma, non-small-cell lung - drug therapy (189) 189
epidermal growth factor receptor (180) 180
adult (172) 172
mice (153) 153
chemotherapy (152) 152
receptor, epidermal growth factor - genetics (146) 146
epidermal growth factor (140) 140
lung-cancer (138) 138
quinazolines - administration & dosage (137) 137
trial (135) 135
monoclonal-antibody (116) 116
treatment outcome (116) 116
lung neoplasms - pathology (109) 109
pharmacology & pharmacy (108) 108
tyrosine kinase (107) 107
breast-cancer (104) 104
phosphorylation (103) 103
quinazolines - adverse effects (102) 102
protein kinase inhibitors - pharmacology (101) 101
inhibitor (100) 100
epidermal-growth-factor (98) 98
apoptosis (97) 97
tumors (97) 97
aged, 80 and over (95) 95
erlotinib (94) 94
mutation (94) 94
dose-response relationship, drug (92) 92
antineoplastic agents - adverse effects (91) 91
cetuximab (91) 91
protein-tyrosine kinases - antagonists & inhibitors (91) 91
mutations (90) 90
antibodies, monoclonal, humanized (89) 89
apoptosis - drug effects (88) 88
erlotinib hydrochloride (87) 87
lung cancer (87) 87
combination (86) 86
antineoplastic combined chemotherapy protocols - therapeutic use (85) 85
signal transduction - drug effects (85) 85
neoplasms - drug therapy (84) 84
signal transduction (84) 84
solid tumors (82) 82
drug resistance, neoplasm (81) 81
phase-ii trial (81) 81
breast neoplasms - drug therapy (80) 80
protein kinase inhibitors - therapeutic use (80) 80
cell proliferation - drug effects (79) 79
egf receptor (77) 77
mice, nude (76) 76
non-small cell lung cancer (75) 75
antitumor-activity (73) 73
care and treatment (73) 73
carcinoma (72) 72
carcinoma, non-small-cell lung - pathology (72) 72
respiratory system (71) 71
breast cancer (69) 69
lung neoplasms - genetics (68) 68
lung cancer, non-small cell (66) 66
phase-ii (66) 66
quinazolines - pharmacokinetics (65) 65
tumor cells, cultured (65) 65
in-vitro (64) 64
in-vivo (64) 64
tyrosine (64) 64
antineoplastic agents - administration & dosage (63) 63
antibodies, monoclonal - therapeutic use (62) 62
blotting, western (62) 62
receptor, erbb-2 - metabolism (62) 62
research (62) 62
phase-i (61) 61
prognosis (61) 61
tyrosine kinase inhibitors (59) 59
clinical trials as topic (58) 58
egfr mutations (57) 57
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CANCER RESEARCH, ISSN 0008-5472, 10/2004, Volume 64, Issue 20, pp. 7241 - 7244
Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) have recently been described in patients with non-small-cell... 
BREAST-CANCER | TRIAL | GROWTH-FACTOR RECEPTOR | ONCOLOGY | ZD1839 IRESSA | SENSITIVITY | TYROSINE KINASE INHIBITOR | MESOTHELIOMA | MUTATIONS | CHEMOTHERAPY | PACLITAXEL
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 12/2018, Volume 61, Issue 24, pp. 11372 - 11383
Adenosine triphosphate (ATP)-competitive inhibitors of the epidermal growth factor receptor (EGFR) have provided a significant improvement in the disease... 
CELL LUNG-CANCER | BREAST-CANCER | GEFITINIB | CHEMISTRY, MEDICINAL | POLYAMMONIUM MACROCYCLES | GROWTH | COMBINATION | ANTAGONISTS | RECEPTOR TYROSINE KINASE | ZD1839 | ERBB RECEPTORS
Journal Article
Oncogene, ISSN 0950-9232, 05/2003, Volume 22, Issue 18, pp. 2812 - 2822
Journal Article
NATURE REVIEWS CANCER, ISSN 1474-175X, 12/2004, Volume 4, Issue 12, pp. 956 - 965
Twenty years after the epidermal growth factor receptor (EGFR) was identified as a potential anticancer target, the EGFR inhibitor gefitinib (Iressa;... 
CELL LUNG-CANCER | BREAST-CANCER | AGENT GEFITINIB | INHIBITOR ZD1839 | PHASE-II TRIAL | ONCOLOGY | ANTICANCER THERAPY | EPIDERMAL-GROWTH-FACTOR | MONOCLONAL-ANTIBODY | EGFR MUTATIONS | RECEPTOR TYROSINE KINASE
Journal Article
PLOS ONE, ISSN 1932-6203, 09/2011, Volume 6, Issue 9
The tyrosine kinase inhibitor gefitinib inhibits growth in some tumor types by targeting the epidermal growth factor receptor (EGFR). Previous studies show... 
SIGNAL-TRANSDUCTION | BREAST-CANCER | LUNG-CANCER | AFFINITY | TYROSINE KINASE | ZD1839 IRESSA | BIOLOGY | TUMOR-CELLS | INHIBITOR | EGFR | LIVING CELLS
Journal Article
Journal of Neurosurgery, ISSN 0022-3085, 09/2018, Volume 129, Issue 3, pp. 598 - 610
OBJECTIVE Glioblastoma is the most common primary central nervous system tumor in adults. These tumors are highly invasive and infiltrative and result in tumor... 
Invadopodia | Oncology | Temozolomide | Glioma | Radiotherapy | Invasion | temozolomide | SURGERY | CANCER | oncology | CLINICAL NEUROLOGY | MALIGNANT GLIOMA | invadopodia | invasion | HUMAN GLIOBLASTOMA CELLS | ZD1839 IRESSA | GROWTH | radiotherapy | glioma | TYROSINE KINASE INHIBITOR | IONIZING-RADIATION | EXPRESSION | BRAIN
Journal Article
Journal Article
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 02/2006, Volume 66, Issue 3, pp. 1630 - 1639
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2004, Volume 22, Issue 5, pp. 785 - 794
Journal Article